Growing CRO footprint Epistem is an established contract research organization with a broad preclinical service portfolio including toxicology, histology, biomarker testing and specialized low input genetic analysis. This positions the company to upsell integrated preclinical packages to pharma and biotech clients seeking one‑stop outsourcing for drug discovery programs.

Global client base With experience supporting over 200 pharmaceutical and biotech customers across oncology, inflammatory, dermatology, auto-immune and GI indications, Epistem has demonstrated market reach and repeat business potential. Targeting mid to late stage pipelines from existing accounts could yield expanded service uptake and longer engagement cycles.

Advanced biomarker niche The proprietary low input gene expression and DNA genotyping capabilities, including single cell inputs and hair follicle–based biomarker techniques, differentiate Epistem. This can be leveraged to win projects requiring minimal sample material or novel biomarker strategies, particularly for rare samples or precision medicine programs.

Upcoming engagement Frequent conference participation and recent expansions into events such as AACR and ESMO provide high‑touch outreach opportunities. Sales teams can align targeted outreach with conference attendance dates, offering tailored preclinical and biomarker packages to attendees and exhibitors.

Growth through partnerships With a revenue range of one to ten million and leadership hiring in business development, Epistem appears positioned to scale through strategic collaborations, co‑development, or preferred supplier arrangements with pharma, biotech, and academic partners seeking flexible, GMP‑compliant preclinical and biomarker services.